Understanding the diverse biochemical and molecular processes of the heart has been limited by the lack of appropriate cell lines. In this application we propose to develop cardiocyte cell lines. Studies on the mechanism of cellular transformation suggest that activation of one or more oncogenes can be used to perpetuate cell growth and division and has proven to be useful method for cell immortalization. Further, recent advances in our analysis of the gene encoding the cardiac-specific peptide, atrial natriuretic factor (ANF), provide a new set of tools that permit activation of particular genes exclusively in the atria and ventricle. We propose to use these genetic tools to target oncogenes to cardiac myocytes. Specifically, we will construct hybrid genes bearing ANF regulatory sequences fused to oncogene sequences. These will be initially introduced into primary cultured cardiocytes derived from neonatal rats. Constructs which are appropriately expressed in primary cultures will be stably introduced into the mouse germline using a transgenic mouse system. Analyses of hearts and primary cultured cardiocytes derived from ANF- oncogene transgenic mice should provide insights into physiologic and pathologic myocardial growth and hypertrophy. Cardiac tissues derived from transgenic mice will be used to develop stable cell lines. These lines should be a valuable resource to investigate many aspects of myocardial cellular and molecular biology.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
1R29HL041474-01
Application #
3472370
Study Section
Cardiovascular Study Section (CVA)
Project Start
1988-07-01
Project End
1993-06-30
Budget Start
1988-07-01
Budget End
1989-06-30
Support Year
1
Fiscal Year
1988
Total Cost
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02115
Pollak, M R; Chou, Y H; Marx, S J et al. (1994) Familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Effects of mutant gene dosage on phenotype. J Clin Invest 93:1108-12
MacRae, C A; Watkins, H C; Jarcho, J A et al. (1994) An evaluation of ribonuclease protection assays for the detection of beta-cardiac myosin heavy chain gene mutations. Circulation 89:33-5
Solomon, S D; Wolff, S; Watkins, H et al. (1993) Left ventricular hypertrophy and morphology in familial hypertrophic cardiomyopathy associated with mutations of the beta-myosin heavy chain gene. J Am Coll Cardiol 22:498-505
Watkins, H; MacRae, C; Thierfelder, L et al. (1993) A disease locus for familial hypertrophic cardiomyopathy maps to chromosome 1q3. Nat Genet 3:333-7
Watkins, H; Thierfelder, L; Anan, R et al. (1993) Independent origin of identical beta cardiac myosin heavy-chain mutations in hypertrophic cardiomyopathy. Am J Hum Genet 53:1180-5
Thierfelder, L; MacRae, C; Watkins, H et al. (1993) A familial hypertrophic cardiomyopathy locus maps to chromosome 15q2. Proc Natl Acad Sci U S A 90:6270-4
Watkins, H; Thierfelder, L; Hwang, D S et al. (1992) Sporadic hypertrophic cardiomyopathy due to de novo myosin mutations. J Clin Invest 90:1666-71
Watkins, H; Rosenzweig, A; Hwang, D S et al. (1992) Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med 326:1108-14
Watkins, H; Seidman, C E; MacRae, C et al. (1992) Progress in familial hypertrophic cardiomyopathy: molecular genetic analyses in the original family studied by Teare. Br Heart J 67:34-8
Rosenzweig, A; Seidman, C E (1991) Atrial natriuretic factor and related peptide hormones. Annu Rev Biochem 60:229-55

Showing the most recent 10 out of 16 publications